EPIDIOLEX® (cannabidiol) oral solution: Now FDA Approved, Pending Rescheduling
Click here to see Press Release.

Sign up here to receive EPIDIOLEX information and availability updates.

Therapeutic Areas


Our pipeline in the field of epilepsy currently includes two product candidates: Epidiolex® (cannabidiol or CBD) and GWP42006 (cannabidivarin or CBDV). Currently, there are no planned trials for CBDV in the U.S.

Epidiolex (CBD) is a liquid formulation of pure plant-derived cannabidiol and is being investigated as a treatment for various orphan childhood-onset epilepsy syndromes. We have been conducting pre-clinical research of CBD in epilepsy since 2007. Based upon research using a variety of in vitro and in vivo models, we have progressed into clinical trials. 

Our strategy for the development of Epidiolex (CBD) within the field of childhood-onset epilepsy is to initially concentrate formal development efforts on four orphan indications: DS, LGS, TSC, and IS, each of which are severe infantile-onset, drug-resistant epilepsy syndromes. We expect to investigate additional orphan seizure disorders.

Epidiolex (CBD) is an investigational drug not approved for any indication.